Joseph Lewis
CIK 1015747 · last filed 2024-11-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ITOS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
LEWIS DRIVE
NEW PROVIDENCE N7776
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| INSG | 10%+ Owner | 1,800,186 | $4.19 | $7.54M | $58.52M | 10 | 2024-11-12 |
| iTeos Therapeutics, Inc. (ITOS) Delisted | 10%+ Owner | 2,946,915 | $10.15 | $29.91M | -$223.71M | 3 | 2024-05-14 |
| TNGX | 10%+ Owner | 8,203,642 | $23.53 | $193.03M | $45.75M | 2 | 2023-10-17 |
| Odonate Therapeutics, Inc. (ODT) Delisted | 10%+ Owner | 4,757,086 | $1.12 | $5.33M | -$6.19M | 1 | 2021-11-19 |
| Carisma Therapeutics Inc. (EBIO) Delisted | 10%+ Owner | 1,390,712 | — | — | -$11.44M | 1 | 2016-06-14 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | 10%+ Owner | 522,500 | $58.70 | $30.67M | $38.12M | 2 | 2015-09-18 |
| SOPHIRIS BIO INC. (SPHS) Delisted | 10%+ Owner | 161,447 | — | — | -$2.15M | 1 | 2014-12-17 |
Recent Filings · Page 2 of 2
20 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-09-24 | INSG | Mixed | +2,121,290 | $0 | EDGAR |
| 2021-07-30 | INSG | Grant (A) | +28,442 | $0 | EDGAR |
| 2021-05-11 | INSG | Grant (A) | +12,484 | $0 | EDGAR |
| 2019-08-13 | INSG | Grant (A) | +14,000 | $14.00M | EDGAR |
| 2019-03-29 | INSG | Mixed | +6,332,550 | $15.96M | EDGAR |
| 2018-12-20 | INSG | Buy (P) | +19,505,458 | $58.52M | EDGAR |
| 2016-06-14 | Carisma Therapeutics Inc. (EBIO) Delisted | Sell (S) | −4,168,000 | -$11.44M | EDGAR |
| 2015-09-18 | Mirati Therapeutics, Inc. (MRTX) Delisted | Mixed | +225,000 | $10.12M | EDGAR |
| 2014-12-17 | SOPHIRIS BIO INC. (SPHS) Delisted | Sell (S) | −3,525,916 | -$2.15M | EDGAR |
| 2013-10-28 | Mirati Therapeutics, Inc. (MRTX) Delisted | Buy (P) | +1,600,000 | $28.00M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.